Exploring Nanoemulsion for Liver Cancer Therapy

Cancer is a leading cause of mortality worldwide, accounting for 8.8 million deaths in 2015. Among these, at least 0.78 million people died of liver cancer alone. The recognized risk factors for liver cancer include chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, exposure to dietary aflatoxin, fatty liver disease, alcohol-induced cirrhosis, obesity, smoking, diabetes, and iron overload. The treatment plan for early diagnosed patients includes radiation therapy, tumour ablation, surgery, immunotherapy, and chemotherapy. Some sort of drug delivery vehicles has to be used when the treatment plan is targeted chemotherapy. Nanoemulsions are a class of biphasic liquid dosage form which are mixtures of oil and water stabilized by a surfactant. They are either transparent or bluish in hue and serve as a wonderful carrier system for chemotherapeutic drugs. These vehicles have a particle size in the range of 20-200 nm allowing them to be delivered successfully in the deepest of tissues. Recent publications on nanoemulsions reveal their acceptance and a popular choice for delivering both synthetic and herbal drugs to the liver. This work focuses on some anti-cancer agents that utilized the advantages of nanoemulsion for liver cancer therapy.

Download Full-text

Using Chitosan or Chitosan Derivatives in Cancer Therapy

Polysaccharides ◽

10.3390/polysaccharides2040048 ◽

2021 ◽

Vol 2 (4) ◽

pp. 795-816

Author(s):

Md Salman Shakil ◽

Kazi Mustafa Mahmud ◽

Mohammad Sayem ◽

Mahruba Sultana Niloy ◽

Sajal Kumar Halder ◽

...

Keyword(s):

Drug Delivery ◽

Cancer Therapy ◽

Anticancer Agents ◽

Chitosan Nanoparticles ◽

Chemotherapeutic Drugs ◽

Chitosan Derivatives ◽

Drug Delivery Vehicles ◽

Modified Chitosan ◽

Therapeutic Benefits ◽

Delivery Vehicles

Cancer is one of the major causes of death worldwide. Chemotherapeutic drugs have become a popular choice as anticancer agents. Despite the therapeutic benefits of chemotherapeutic drugs, patients often experience side effects and drug resistance. Biopolymers could be used to overcome some of the limitations of chemotherapeutic drugs, as well as be used either as anticancer agents or drug delivery vehicles. Chitosan is a biocompatible polymer derived from chitin. Chitosan, chitosan derivatives, or chitosan nanoparticles have shown their promise as an anticancer agent. Additionally, functionally modified chitosan can be used to deliver nucleic acids, chemotherapeutic drugs, and anticancer agents. More importantly, chitosan-based drug delivery systems improved the efficacy, potency, cytotoxicity, or biocompatibility of these anticancer agents. In this review, we will investigate the properties of chitosan and chemically tuned chitosan derivatives, and their application in cancer therapy.

Download Full-text

Transgenic mouse models generated by hydrodynamic transfection for genetic studies of liver cancer and preclinical testing of anti-cancer therapy

International Journal of Cancer ◽

10.1002/ijc.29703 ◽

2015 ◽

Vol 138 (7) ◽

pp. 1601-1608 ◽

Cited By ~ 6

Author(s):

Hye-Lim Ju ◽

Kwang-Hyub Han ◽

Jong Doo Lee ◽

Simon Weonsang Ro

Keyword(s):

Cancer Therapy ◽

Liver Cancer ◽

Transgenic Mouse ◽

Mouse Models ◽

Transgenic Mouse Models ◽

Genetic Studies ◽

Preclinical Testing ◽

Anti Cancer ◽

Hydrodynamic Transfection

Download Full-text

Cancer therapy based on extracellular vesicles as drug delivery vehicles

Journal of Controlled Release ◽

10.1016/j.jconrel.2020.08.018 ◽

2020 ◽

Vol 327 ◽

pp. 296-315 ◽

Cited By ~ 2

Author(s):

Laura Cabeza ◽

Gloria Perazzoli ◽

Mercedes Peña ◽

Ana Cepero ◽

Cristina Luque ◽

...

Keyword(s):

Drug Delivery ◽

Cancer Therapy ◽

Extracellular Vesicles ◽

Drug Delivery Vehicles ◽

Delivery Vehicles

Download Full-text

Extracellular Matrix Component Shelled Nanoparticles as Dual Enzyme-Responsive Drug Delivery Vehicles for Cancer Therapy

ACS Biomaterials Science & Engineering ◽

10.1021/acsbiomaterials.8b00327 ◽

2018 ◽

Vol 4 (7) ◽

pp. 2404-2411 ◽

Cited By ~ 14

Author(s):

Juan Zhou ◽

Mingyu Wang ◽

Huiyan Ying ◽

Dandan Su ◽

Huijie Zhang ◽

...

Keyword(s):

Drug Delivery ◽

Extracellular Matrix ◽

Cancer Therapy ◽

Extracellular Matrix Component ◽

Matrix Component ◽

Drug Delivery Vehicles ◽

Delivery Vehicles

Download Full-text

QIM19-118: Oral Anti-Cancer Therapy Initiation: A Standardized Approach for Patient Care and Education

Journal of the National Comprehensive Cancer Network ◽

10.6004/jnccn.2018.7113 ◽

2019 ◽

Vol 17 (3.5) ◽

pp. QIM19-118

Author(s):

Megan Corbett ◽

Cynthia Arcieri ◽

Emma Dann ◽

Jeff Durney ◽

Frances Fuller ◽

...

Keyword(s):

Quality Improvement ◽

Patient Education ◽

Cancer Therapy ◽

Patient Care ◽

Treatment Plan ◽

Care Team ◽

Educational Materials ◽

Extended Care ◽

Anti Cancer ◽

Adherence Monitoring

Background: The availability and popularity of oral anti-cancer therapy has recently increased. In this shift of delivery, control over downstream steps in the process moves to patients, families, and the extended care team. Unique challenges have been identified including effective patient education, adherence, and monitoring. The purpose of this quality improvement project was to standardize the approach to initiating oral anti-cancer patient care. Methods: A quality improvement team developed and implemented a standard approach for before, during, and after initiation of oral anti-cancer therapy. Key components included ensuring completion of informed consent, electronic orders within an evidence-based treatment plan, and adherence monitoring with a specific emphasis on patient education. Education prior to initiating therapy was standardized through both an education folder and one-on-one teaching sessions with an oncology nurse. A voluntary, anonymous 4-question paper survey (deemed clinical quality improvement by the IRB) solicited feedback from patients to assess both the educational materials and teaching session. Questions included perceived acceptability of the content and whether materials guided conversation, provoked questions, and complimented the teaching. An opportunity for comments was provided. Results: A 3-month collection period yielded overwhelmingly positive results. 100% of patients (n=18) felt the education materials provided were “just right” and provoked discussion with the care team. 94% of patients felt the educational materials and teaching session were complimentary. Conclusions: As oral anti-cancer therapy becomes more common, it is vital to form a collaborative partnership with the patient, family, and the extended care team to ensure overall success. Standardized educational content supports the transfer of expert knowledge to ensure adherence, management, and patient safety, ultimately improving patient outcomes. A standard approach that includes informed consent, orders within a treatment plan, adherence monitoring, and patient education prior to initiating oral anti-cancer therapy is one way to ensure quality, comprehensive patient care.

Download Full-text